Cambridge, UK-founded biomolecule quantification company Abselion has established a US subsidiary at The Engine in Cambridge, MA. The company says the new location will provide a formal base to support more direct engagement with US academic, biotech, and pharma research teams working across biologics characterisation and development workflows. The Engine, built by the Massachusetts Institute […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!